Gosset Iksuda Therapeutics General Information
Iksuda’s clinical-stage ADC pipeline includes multiple programs targeting both hematologic malignancies and solid tumors. Lead assets such as the anti-CD19 ADC (“IKS03”) and HER2-targeting ADC (“IKS014”) have entered Phase I clinical trials. The company emphasizes tumor-selective activation of novel prodrug payloads to improve therapeutic index. Early results validate their approach for improved safety/efficacy profiles compared to traditional ADC designs.[1][5][6] Pipeline breadth: At least four named clinical/preclinical programs plus an expanding early-stage portfolio.[5]
Contact Information
United Kingdom
Drug Pipeline
Key Partnerships
LegoChem Biosciences / LigaChem BioSciences – licensing of ConjuAll platform, anti-CD19 & HER2-directed assets, major equity investment ($25M in March 2025)[7][5]., Research collaborations with leading academic institutions for binder discovery/enhancement.[4]
Iksuda Therapeutics Funding
No funding data available